Download PDF
TumorDiagnostik & Therapie 2005; 26(4): 161-165
DOI: 10.1055/s-2005-858477
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Molekulare Bildgebung bei gastrointestinalen Stromatumoren: Rolle der Positronen-Emissions-Tomographie mit [18F]-2-Fluordeoxyglukose

Molecular Imaging in Gastrointestinal Stromal Tumors: Role of [18F]-Fluorodeoxyglucose Positron Emission TemographyL. Freudenberg1 , J. Schütte2 , S. Rosenbaum1 , R. Pink1 , G. Antoch3 , A. Bockisch1
  • 1Klinik für Nuklearmedizin, Universitätsklinikum Essen, Deutschland
  • 2Klinik für Onkologie und Hämatologie, Marien-Hospital Düsseldorf, Deutschland
  • 3Institut für Diagnostische und Interventionelle Radiologie und Neuradiologie, Universitätsklinikum Essen, Deutschland
Further Information

Publication History

Publication Date:
09 August 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die metabolische Bildgebung mit [18F]-2-Fluordeoxyglukose-Positronen-Emissions-Tomographie (FDG-PET) ermöglicht über die Darstellung des Glukosestoffwechsels die Diagnostik von vitalen Tumormanifestationen bei GIST mit hoher Sensitivität. Da bei Patienten mit gastrointestinalen Stromatumoren ein signifikantes metabolisches Therapieansprechen unter Therapie mit dem Tyrosinkinaseinhibitor Imatinib direkt nach Therapiebeginn zu verzeichnen ist, eignet sich die FDG-PET hervorragend in der Therapiekontrolle und ist den herkömmlichen anatomischen Bildgebungsverfahren, insbesondere der Computertomographie (CT), signifikant überlegen. FDG-PET erlaubt die Beurteilung des Therapieeffektes schneller (zum Teil innerhalb von 24 h nach Therapiebeginn) und zuverlässiger als alle anderen Untersuchungsmodalitäten. Die FDG-PET ist somit Methode der Wahl, um ein funktionelles Therapieansprechen zu beurteilen. Eine kombinierte FDG-PET/CT-Bildgebung scheint darüber hinaus insbesondere vor etwaigen Interventionen eine zusätzliche Verbesserung der Diagnostik zu ermöglichen.

Abstract

Metabolic imaging using positron emission tomography (PET) employing the radiotracer [18F]-fluorodeoxyglucose (FDG) is highly sensitive in staging of gastrointestinal stromal tumor (GIST) by highlighting tumor glucose metabolism. Compared to morphological imaging with computed tomography (CT) the use of FDG-PET has been shown to improve the assessment of tumor behaviour and correlates closely with early metabolic tumor response to imatinib mesylate. Consequently, FDG-PET is the diagnostic tool of choice with a high sensitivity and specifity for evaluation of treatment response in GIST. Furthermore, newly available combined FDG-PET/CT precisely delineates lesions and thus allows optimised planning of surgical interventions.

Schlüsselwörter

Gastrointestinale Stromatumoren (GIST) - Positronen-Emissions-Tomographie (PET) - [18F]-2-Fluordeoxyglukose (FDG)

Key words

Gastrointestinal stromal tumor (GIST) - positron emission tomography (PET) - [18F]-fluorodeoxyglucose (FDG)

Literatur

  • 1 Janicek M J, Potter A, Demetrie G D. Does pattern of metastases and early measurable changes after treatment predict therapy effect in gastrointestinal stromal tumor (GIST) on STI 571 (Imatinib)?.  Radiology. 2002;  225 (S) 583
    CrossrefPubMedGoogle Scholar
  • 2 Reichardt P, Pink D, Hohenberger P. Paradigmenwechsel in der Therapie gastrointestinaler Stromatumoren.  Onkologe. 2002;  8 378-383
    CrossrefPubMedGoogle Scholar
  • 3 Demetri G D. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).  Eur J Cancer. 2002;  38 (5) 52-59
    PubMedGoogle Scholar
  • 4 Warburg 0. The metabolism of tumors. New York; Richard R. Smith Inc. 1930: 129-169
    Google Scholar
  • 5 Engel H, Steinert H, Buck A. et al . Whole-body PET: physiologic and artifactual fluoro-deoxyglucose accumulations.  J Nucl Med. 1996;  37 441-446
    PubMedGoogle Scholar
  • 6 Lindholm P, Minn H, Leskinen-Kallio S. et al . Influence of the blood glucose concentration on FDG uptake in cancer - a PET study.  J Nucl Med. 1993;  34 1-6
    PubMedGoogle Scholar
  • 7 Jones T. The imaging science of positron emission tomography.  Eur J Nucl Med. 1996;  23 (7) 807-813
    PubMedGoogle Scholar
  • 8 Weber W A, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging.  Nucl Med Biol. 2000;  27 (7) 683-687
    PubMedGoogle Scholar
  • 9 Young H, Baum R, Cremerius U. et al . Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.  Eur J Cancer. 1999;  35 (13) 1773-1782
    CrossrefPubMedGoogle Scholar
  • 10 Gambhir S S, Czernin J, Schwimmer J. et al . A Tabulated Summary of the FDG PET Literature.  J Nucl Med. 2001;  42 1-93
    PubMedGoogle Scholar
  • 11 Knapp W H. Leitlinie zur Tumordarstellung mit (F-18)-Fluordeoxyglukose (FDG).  Nuklearmedizin. 1999;  38 267-269
    PubMedGoogle Scholar
  • 12 Reske S N, Kotzerke J. FDG-PET for clinical use Results of the 3rd German Interdisciplinary Consensus Conference, „Onko-PET III”, 21.7.2000 and 19.9.2000.  Eur J Nucl Med. 2001;  28 1707-1723
    Google Scholar
  • 13 Römer W, Hanauske A R, Ziegler S. et al . Positron Emission Tomography in Non-Hodgkin’s Lymphoma: Assessment of Chemotherapy with Fluorodeoxyglucose.  Blood. 1998;  91 4464-4471
    PubMedGoogle Scholar
  • 14 Hicks R J, Kalff V, Mac M anus MP. et al . The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.  J Nucl Med. 2001;  42 1605-1613
    PubMedGoogle Scholar
  • 15 Hicks R J, Kalff V, Mac M anus MP. et al . (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.  J Nucl Med. 2001;  42 1596-1604
    PubMedGoogle Scholar
  • 16 Van den Abbeele A D, Badawi R D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).  Eur J Cancer. 2002;  38 (5) 60-65
    CrossrefPubMedGoogle Scholar
  • 17 Van Oosterom A T, Judson I, Verweij J. et al . European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.  Lancet 2001. 358 (9291) 1421-1423
    PubMedGoogle Scholar
  • 18 Van Oosterom A T, Judson I R, Verweij J. et al . European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.  Eur J Cancer. 2002;  38 (5) 83-87
    CrossrefPubMedGoogle Scholar
  • 19 Van den Abbeele A D, Badawi R D, Tetrault R J. et al . FDG-PET as a surrogate marker for response to Gleevec™ (imatinib mesylate) in patients with advanced gastrointestinal stromal tumors (GIST). Abstract 77.  SNM. 2003; 
    PubMedGoogle Scholar
  • 20 Jager P L, Gietema J A, van der Graaf W T. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.  Nucl Med Commun. 2004;  25 (5) 433-438
    CrossrefPubMedGoogle Scholar
  • 21 Antoch G, Kanja J, Bauer S. et al . Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.  J Nucl Med. 2004;  45 (3) 357-365
    PubMedGoogle Scholar
  • 22 Bauer S, Corless C L, Heinrich M C. et al . Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.  Cancer Chemother Pharmacol. 2003;  51 261-265
    PubMedGoogle Scholar
  • 23 Choi H, Charnsangavej C, de Castro F aria S. et al . CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.  AJR Am J Roentgenol. 2004;  183 (6) 1619-1628
    PubMedGoogle Scholar
  • 24 Van den Abbeele A, Badawi R D, Clic J P. et al .18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Presented at ASCO 2002, Abstract 1610. 
    Google Scholar
  • 25 Stroobants S, Goeminne J, Seegers M. et al . 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).  Eur J Cancer. 2003;  39 (14) 2012-2020
    CrossrefPubMedGoogle Scholar
  • 26 Gelibter A, Milella M, Ceribelli A. et al . PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients.  Anticancer Res. 2004;  24 (5B) 3147-3151
    PubMedGoogle Scholar
  • 27 Gayed I, Vu T, Iyer R. et al . The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.  J Nucl Med. 2004;  45 (1) 17-21
    PubMedGoogle Scholar
  • 28 Goerres G W, Stupp R, Barghouth G. et al . The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.  Eur J Nucl Med Mol Imaging. 2005;  32 (2) 153-162
    CrossrefPubMedGoogle Scholar
  • 29 Boren J, Cascante M, Marin S. et al . Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells.  J Biol Chem. 2001;  276 37 747-37 753
    PubMedGoogle Scholar
  • 30 Zasadny K R, Wahl R L. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction.  Radiology. 1993;  189 (3) 847-850
    PubMedGoogle Scholar
  • 31 Kim C K, Gupta N C. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction.  Nucl Med Commun. 1996;  17 (10) 890-894
    PubMedGoogle Scholar
  • 32 Beyer T, Townsend D W, Brun T. et al . A Combined PET/CT Scanner for Clinical Oncology.  J Nucl Med. 2000;  41 1369-1379
    PubMedGoogle Scholar

Dr. med. Lutz S. Freudenbergž M.A., M.B.A.

Dipl.-Gesundheitsökonom (BI), Klinik für Nuklearmedizin, Universität Essen

Hufelandstraße 55

45122 Essen

Phone: ++ 49/2 01/7 23-20 32

Fax: ++ 49/2 01/7 23-59 64

Email: lutz.freudenberg@uni-essen.de

      >